Development of a New Medicine Used in the Therapy of Solid Tumors Metastasis to Lungs
Annamycin belongs to the group of anthracyclines, considered one of the most effective groups of oncological drugs. Unlike clinically used anthracyclines, Annamycin, thanks to modifications in the drug structure, effectively penetrates cancer cells, regardless of the presence of MDR proteins, while maintaining high safety and lack of cardiotoxicity. L-ANN mechanism of action is based on the fixation of cracks in DNA leading to cell apoptosis and suppression of TOPO-II repair activity, which is highly active in cells with high proliferative potential.
Annamycin was originally developed for the treatment of relapsed or refractory acute myeloid leukemia or AML and has been tested in 6 prior clinical trials where 114 patients were treated. Moreover, a low incidence of side effects, especially cardiotoxicity, is observed with L-ANN administration, which is a unique feature among anthracyclines.
Lately, preclinical studies have shown that very high Annamycin concentration in the lungs (6-10 times higher than in plasma) correlates with high drug activity against lung tumors. That is why Annamycins was selected as a promising drug in the treatment of solid tumors metastasis to lungs.
Annamycin is now administrated in two separate Phase I/II clinical trials in AML, one in the US and one in Poland. Moreover, it is in preclinical development on solid tumors. The clinical study on Annamycin in the treatment of solid tumors metastasis to lungs is planned to start in 2021/2022.
Grants / Funding
Liposomal Annamycin is now in the clinical development for the treatment of AML in Europe and US.
Partners, Affiliations & License
MD Anderson, leading cancer research center in the world
Moleculin Biotech, Inc. – co-development partner
WPD owns the rights to chosen countries.
WPD owns the exclusive global rights
With no other curative options available, we believe WPD102 may have the potential for accelerated approval as a safe and effective therapy for primary UV. Moreover, other types of cancer that will be confirmed as IL-13RA2, could potentially be explored as WPD102 targets.
The expected market size is in excess of $1 Billion.